DUBAI, UAE, Jan. 8, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, is excited to unveil a new milestone for Mantle Vault on Bybit On-Chain Earn as its assets under management (AUM) surpassed US$100 million today. Crafted in partnership with Mantle and Cian, Mantle Vault redefines consistency, access, and flexibility in stablecoin on-chain yield generation through market-neutral strategies.

In less than three weeks after its launch, Mantle Vault has rapidly scaled to become one of the most sought-after structured yield products in the on-chain economy available among CEX, demonstrating strong market demand for institutional-grade DeFi solutions that combine flexible access, transparent execution, and dependable returns.

Maintaining APR above 7% since it became part of Bybit Earn‘s product suite, Mantle Vault continues to deliver competitive returns through delta-neutral strategies deployed across audited protocols including Aave V3, generating yield from stablecoin lending, staking rewards, and protocol incentives. The inclusive product balances attractive returns and flexible liquidity, with most withdrawals processed within 0–3 days, zero subscription fees, and a low entry threshold starting at just 10 USDT or USDC.

Gateway to New Era of Access to On-Chain Finance

Mantle Vault represents a step forward in the convergence of centralized distribution and decentralized execution, enabling users to access market-neutral, onchain yield strategies through a familiar CeFi interface while retaining the transparency, composability, and efficiency of DeFi.

With over $100 million AUM and counting, its popularity attests to investor confidence in Mantle’s infrastructure as the execution layer for scalable on-chain strategies, while Bybit’s global distribution network continues to serve as the primary access point for millions of users seeking simplified exposure to sophisticated DeFi yield opportunities.

The revolutionary yield-bearing stablecoin asset management product designed to accelerate the adoption of onchain yield forms part of Bybit Earn and Mantle’s broader real-world asset (RWA) and CeDeFi strategy for 2026.

“Mantle Vault is a clear example of how our RWA mission is accelerating in 2026,” said Emily Bao, Key Advisor at Mantle. “By converging CeFi distribution with fully on-chain yield and execution, this is how Mantle powers institutional-grade DeFi to move from niche use cases to mainstream financial adoption.”

“Users are ready for professionally managed, transparent onchain yield products,” said Jerry Li, Head of Financial Products and Wealth Management at Bybit. “Mantle Vault proves that when you combine institutional infrastructure with user-friendly access, you can deliver DeFi solutions that resonate with both retail and professional investors.”

Product Highlights:

• Proven Performance: Track record of delivering stable, market-neutral returns across varying market conditions
• Institutional Infrastructure: Built on audited smart contracts with assets held on Aave V3 protocol, primarily on Ethereum mainnet
• Full Transparency: Completely onchain execution with real-time visibility into strategy deployment
• Flexible Access: No lock-up periods, with withdrawal requests typically processed within 0–3 days
• Low Barriers to Entry: Minimum deposit of 10 USDT or USDC

The product operates through Cian’s specialized on-chain asset management infrastructure, which abstracts complex DeFi strategies into simple, accessible vaults while maintaining full transparency and composability within Mantle’s low-cost, high-performance execution environment.

Terms and conditions apply. Past APR does not guarantee future APR. It may change due to Aave market demand, Ethena rewards or gas cost fluctuations. For details on qualification rules, restrictions, and eligibility, users may visit: [Bybit x Mantle x Cian] Introducing Mantle Vault: Stablecoin on-chain yield strategy built for stability, flexibility, and scale

#Bybit / #CryptoArk / #IMakeIt

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

MELBOURNE, Australia and INDIANAPOLIS, Jan. 8, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 44^th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.). 

Telix will host a presentation on Monday, 12 January at 9:00 am PST (12:00 pm EST / 4:00 am AEDT, 13 January), providing an overview of the Company’s pipeline assets alongside its commercial portfolio.

The event will be webcast live here and available on demand for 30 days via the Telix Investor Relations website at: ir.telixpharma.com/

In addition to the live presentation and slides, Telix will publish a comprehensive overview of all therapeutic pipeline assets in a dedicated presentation accessible on the Investor Relations website. 

Financials for the fourth quarter of 2025, will be released on 20 January, 2026.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations (Global)

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

United States 
Annie Kasparian
Telix Pharmaceuticals Limited
Director Investor Relations and Corporate Communications
Email: annie.kasparian@telixpharma.com

Media Contact
Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-CDx and the planned BLA resubmission for TLX250-CDx, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

GENEVA, Jan. 8, 2026 /PRNewswire/ — All Here announces the launch of the Bio-Intelligence Initiative, the world’s first research program exploring how deep meditative states of stability and silence of Mind give rise to measurable neural patterns, and how these complex neural signatures may inspire the development of biologically linked, energy-efficient, and adaptive AI systems.

As artificial intelligence systems continue to scale through increased computing power and energy consumption, All Here is advancing an alternative research pathway grounded in the principles of complex decision making enabled by biological intelligence.

All Here launches the world’s first research program exploring how brain states and dynamics deriving from sustained attention can guide the next generation of biological AI systems.

The Bio-Intelligence Initiative investigates how coherent and low-noise neural states observed in the human brain can serve as reference models for training emerging biocomputing and bio-artificial intelligence systems, drawing in particular on the complex neural signatures observed in deep meditative states.

“Biological intelligence operates with extraordinary efficiency, coherence, and adaptability,” said Erkin Bek, Founder of All Here and the World Meditation League. “Through advanced meditation, the human brain can reliably enter stable yet complex states that modern neuroscience is now able to observe and characterize with high precision. Our initiative explores how these states may help create training models and guide the development of future intelligence systems that are not only more efficient, but also more adaptive.”

Attention and Self-Regulation as a Training Model for Organoids

The All Here Bio-Intelligence Initiative approaches meditation not as a philosophical practice, but as a scientifically supported and repeatable method for inducing identifiable neural signatures. These signatures—associated with sustained attention, self-regulation, neural coherence, and low-noise dynamics—are studied as potential blueprints for training models in biological computing systems composed of living human neurons and stem-cell-derived organoids.

Rather than relying on traditional brute-force computation, the initiative explores training frameworks inspired by how the human brain naturally self-organizes under conditions of disciplined attention.

Collaboration and Interdisciplinary Research

The initiative is conducted in collaboration with leading neurobiologists, neuroscientists, and artificial intelligence experts in Switzerland and internationally. By bridging neuroscience, meditation research, and emerging biocomputing technologies, All Here aims to contribute foundational knowledge to the development of next-generation BioAI (Bio Artificial Intelligence).

Addressing the Limits of Silicon-Based AI

Despite rapid progress, silicon-based AI systems increasingly depend on large-scale data centers and escalating energy demands. These approaches lack the adaptive efficiency and self-organizing dynamics inherent to biological intelligence and computation.

The Bio-Intelligence Initiative responds to this challenge by advancing biologically inspired models that emphasize coherence, adaptability, and energy efficiency, offering a research pathway toward more sustainable and adaptive computing systems.

About All Here

All Here is a Geneva-based research and development organization built on three core pillars: Science, Technology and evidence-based Meditation Practice. Through collaboration with leading neuroscientists, high-level practitioners, and world-class institutions, All Here is pioneering the scientific research of the Silent Mind using Quantified Meditation and advanced brain imaging and brain-computer-interface technologies. 

For more information, visit allhere.org.

DUBAI, UAE, Jan. 8, 2026 /PRNewswire/ — Reflecting its strategic business direction, STARTRADER seals a deal with the National Basketball Association (NBA) and becomes the league’s Official Partner, which marks a significant milestone in the company’s continued growth and expansion.

STARTRADER Begins 2026 as Official Partner of the NBA

Fans will see STARTRADER’s brand integrated across key NBA touchpoints. From in-arena backdrops to broadcast-visible placements and select league media platforms, STARTRADER will benefit from high-impact visibility as audiences experience year-round storytelling across digital, broadcast, and select live events. These activations strengthen the brand’s global presence and reinforce its innovative narrative, in addition to joint Social Impact initiatives between the NBA and STARTRADER.

“This collaboration reflects the direction STARTRADER is taking as a global brand,” said Mr. Peter Karsten, CEO of STARTRADER. “Aligning with the NBA reinforces the trust placed in our brand and supports our vision of operating on an international stage alongside institutions that share a commitment to long-term growth.”

“We look forward to working closely with STARTRADER as we continue to grow basketball and the NBA’s presence across the Middle East,” said NBA Head of Middle East Strategy & Development, David Watts. “The region is a key priority for the league, and this cooperation reflects our ambition to work with brands that share our commitment to engaging fans using the latest technological innovations.”

The collaboration aligns with STARTRADER’s repositioning, ‘Built on Trust, Driven by Growth.’ It reflects the growth that the brand has achieved as it continues to cooperate with global-level institutions that carry long-standing influence across cultures and markets.

At the core of this direction is STARTRADER’s focus on making global trading accessible and trusted, and empowering principles that mirror the NBA’s role in connecting hundreds of millions of fans worldwide around the game of basketball. Through transparent access, advanced tools, and trusted support, STARTRADER builds a trading environment that enables traders and partners to grow with confidence.

As the NBA celebrates its 80^th season, STARTRADER remains committed to the strong foundations it has built over the years to support long-term growth in an evolving financial landscape. The collaboration signals STARTRADER’s continued evolution as a global brand operating on the world stage.

ABOUT STARTRADER

As a globally leading broker, STARTRADER provides a transparent trading environment and exceptional services to clients in over 200 regions worldwide. We offer a wide range of trading products, including forex, precious metals, stocks, indices, commodities, and ETFs, along with diverse platforms. Additionally, we showcase our comprehensive service capabilities by providing tailored liquidity solutions for institutional clients, securing a unique position in the industry. STARTRADER is regulated by five top-tier authorities—SCA, ASIC, FSCA, FSA, and FSC—ensuring the highest standards of security and trust for our clients. https://www.startrader.com/

SHANGHAI, Jan. 8, 2026 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced that China’s National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules (Aizhida) for treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older in China.

Aizhida is a central nervous system stimulant indicated for the treatment of ADHD. Each once-daily capsule contains serdexmethylphenidate (SDX), a prodrug of dexmethylphenidate, co-formulated with immediate-release dexmethylphenidate (d-MPH) in a fixed ratio designed to provide both rapid and extended symptom control.After ingestion, the immediate-release d-MPH component is rapidly absorbed to provide early onset of effect, while SDX is gradually converted to d-MPH in the lower gastrointestinal tract, supporting sustained therapeutic exposure throughout the day. Aizhida was approved by the U.S. FDA in March 2021 as a once-daily treatment option for patients with ADHD 6 years of age and older.

ADHD is a common, chronic neurodevelopmental disorder that typically begins in childhood and may persist into adulthood. It is primarily characterized by age-inappropriate levels of inattention and/or hyperactivity-impulsivity. In China, the prevalence of ADHD in children and adolescents is estimated at approximately 6.4%, affecting over 23 million individuals. Studies have shown that symptoms persist into adolescence for 60%-80% of patients, and into adulthood for roughly half of cases. Current ADHD treatment options in China are limited, and currently available medications do not fully meet clinical needs in terms of both efficacy and safety for many patients. Some patients discontinue treatment due to suboptimal response, side effects, or dosing inconvenience, highlighting the need for additional therapeutic options.

Robust Clinical Data Addresses Unmet Need: In a pivotal Phase III clinical trial in Chinese patients with ADHD, Aizhida met both the primary and key secondary endpoints. The study demonstrated statistically significant and clinically meaningful improvements in core ADHD symptoms compared to placebo at all assessment time points. With limited treatment options in China and historical supply constraints for traditional single-agent therapies, the approval of this innovative combination product offers an important new choice for clinicians and patients.

Unique Dual Mechanism for Rapid Onset and All-Day Coverage: Aizhida combines immediate-release and prodrug-based extended-release technologies. Its ‘rapid onset + full-day coverage’ profile positions it to reshape the ADHD treatment paradigm in China. As the first ADHD medication in China to deliver both rapid onset and sustained symptom control, it fills a key clinical gap and has the potential to become a preferred treatment option.

Professor Yi Zheng, Chief Expert at Beijing Anding Hospital, Capital Medical University, and Lead Principal Investigator of the Aizhida Phase III trial in China, commented: “ADHD is one of the most common neurodevelopmental disorders in childhood, with potential impact lasting into adulthood, posing long-term challenges to learning, social functioning, and family life. While the prevalence in Chinese children is around 6.4%, treatment options—especially innovative ones balancing efficacy and safety—remain insufficient. The approval of Aizhida provides clinicians with a new therapeutic tool. We anticipate its real-world application will help improve the treatment landscape for ADHD patients in China, offering new hope particularly for those with suboptimal response or tolerance to existing therapies.”

Professor Jing Liu, Director of the Child Psychiatry Center, Peking University Sixth Hospital, and Lead Principal Investigator of the Aizhida Phase III trial in China, added: “We are committed to advancing standardized diagnosis and treatment for pediatric mental disorders in China. Comprehensive intervention is essential for ADHD, with pharmacotherapy being a foundational component. The approval of a new drug not only increases options but also prompts deeper reflection on optimizing treatment strategies. We hope the approval of Aizhida will enrich ADHD treatment approaches and contribute to better long-term outcomes, which is the ultimate goal of our clinical research.”

About ArkBio

ArkBio is a global biotech company focused on developing innovative therapeutics for respiratory and pediatric diseases. Founded in 2014, it has built core technology platforms and a differentiated R&D pipeline through in-house R&D efforts and external collaboration. Key drug assets include ziresovir (AK0529), the first direct-acting RSV antiviral with positive pivotal phase III results, and AK3280, a potentially best-in-class drug with positive phase 2 results to treatment idiopathic pulmonary fibrosis. Another core product Aizhida (AK0901) was recently approved in China for ADHD and has now entered the commercial launch phase. 

ArkBio has established strategic partnerships with several multinational pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions.

For more information, please visit: www.arkbiosciences.com 

Investor Inquiries: IR@arkbiosciences.com